Written by
Share article:
Cranfield, UK, 29th February 2024, Written by Imogen Fitt –
Hello everyone!✨ I hope we all had a lovely February – I’ve been busy planning the scope and segmentation for our new 2024 Digital Pathology Market Intelligence Service, including coverage of telepathology and emerging tech like multiplex-imaging and #generativeAI this year!
Do drop me a note if you’d like to learn more about how we at Signify Research can support your DP strategy, whether you’re a healthcare vendor, investor, lab or partner there’s a number of ways users leverage our data and insights. 😁
#USCAP2024 is also next month! I’m excited to be attending for the first time this year, so reach out if you’d like to connect in person.
Now, onto the news:
- We kicked off the month with Hologic, Inc. announcing FDA approval for its Genius™ Digital Diagnostics System – a significant achievement considering this also included its deep-learning-based cervical algorithm. Hologic already has a significant number of customers it could use to scale commercial activity quickly in the region, and although FDA approval governs only the US, achievements like these often have an uplifting affect on wider geographical markets which perceive FDA approval as mark of quality and vote of confidence. The product is already available in Europe, Australia and New Zealand and I look forward to hearing the commercial results to come this year!
- Next, Paige announced new partners for it’s AppLab marketplace. Imagene, Histofy, Aiosyn, Clinsight analytics DoMore Diagnostics and Stratipath will join Mindpeak GmbH on the platform. The new partners represent a relatively complimentary set of algorithms for Paige to offer to it’s existing user base, whilst also allowing newer vendors a foot-in-the-door as they enter the market. Crucially, Paige is leading this approach through managing the deployments commercially. In this sense, AppLab falls under what we term an ‘AI orchestration platform’. In a previous insightI discussed how AI orchestration platforms benefit customers by enabling a more organised approach to invoices and contracts, alleviating administrative burdens, so it’s fantastic to see this approach being taken.
- On a similar note, Proscia announced the launch of Proscia Ready – a new alliance formed to help labs accelerate DP adoption. The alliance involves joint support agreements which are designed to enable faster resolutions when issues arise for customers. Pramana has already joined the alliance, offering support to labs wanting to realise more value from their pathology data. I again discussed in an earlier insightthat I expected partnerships and interoperability to play an increasingly important role in the market. This announcement takes that a step further via offering customers a single point of contact through which to direct their concerns – I look forward to hearing more vendors join or launch similar initiatives!
- Barco and Applied Spectral Imaging (ASI) announced a commercial agreement allowing ASI promote, market and resell Barco’s MDPC-8127 colour digital pathology display globally. This will allow ASI to expand its product portfolio to further encompass more of the digital pathology value chain and will likely be most relevant to academic medical centres and research institutes as they explore analysis of brightfield, fluorescent and spectral images.
- Back in the UK, NHS England is investing in a learning portal to support the take-up of digital pathology, ensuring that digital learning materials are widely available to prospective users. Reportedly, it also plans to issue guidance soon to support local providers wishing to implement digital pathology for the three cancer screening programmes. Although digital pathology in the UK has received a significant amount of investment in recent years, it’s still important to see initiatives like these which will support an increase in the volumes of slides able to be processed. Many trusts are still starting out their digital pathology journeys!
- Roche entered a collaboration agreement with PathAI. In it, Roche Tissue Diagnostics (RTD) agreed to work exclusively with PathAI to develop AI DP algorithms for RTD’s companion diagnostics business. These will eventually be deployed on Roche’s navify Digital Pathology platform, likely being fully integrated as the company did with Ibex Medical Analytics previously. Whilst Roche will still be able to continue to develop its own algorithms, the partnership is exclusive and PathAI will also still be able to develop algorithms outside of companion diagnostics. A number of vendors are working on developing digital companion diagnostics with pharma, as these can often be an attractive route to market for AI. However, finding a price point for commercial deployment of these algorithms, as well as settling on remuneration upfront can be especially tricky for both parties assuming risk – I’ve seen quite a bit of heterogeneity in this area.
- CellaVision and Sysmex Corporation announced they were reinforcing and extending their joint leadership position within hematology by forming an alliance. Whilst specific details were lacking, the press release noted the two were ‘furthering collaboration within innovation and collaborative commercialisation’. Sysmex’s existing portfolio in hematology, combined with CellaVision’s digital imaging solutions and AI software are complimentary. This move reinforces an existing relationship, perhaps in light of 3DHistech’s recent activity regarding Epredia…?
- Corista announced it had obtained a Class II Medical Device License From Health Canada. Recently the firm has also achieved its CE Mark for European entry, signalling that the vendor may be hoping to more aggressively target international markets in the near-term. Canadian approval is excellent considering Corista’s recent partnership with AGFA HealthCare – according to our Imaging IT market intelligence serviceAgfa is the largest radiology vendor in Canada, possessing a number of Canadian Provincial deals which Corista may now be able to target for digital pathology.
- Techcyte also announced 7 new commercial partners this month. This includes: Thermo Fisher Scientific (Fisher Healthcare) in the US, Quorum Technologies in Canada, Apacor Ltd in the UK and Ireland, CareAbility Healthcare for India, All Eights and All Eights (Malaysia) Sdn Bhd, ProMedica for Serbia, Croatia, Bosnia, Slovenia, and Montenegro; and SSI Diagnostica for Denmark, Sweden, Norway, and Finland. The vendor has made many announcements recently, and is clearly using 2024 to aggressively scale its presence in healthcare!
- Finally, another announcement from Proscia as the company achieved FDA approval for its Concentriq AP-Dx software. This now allows it to be used in primary diagnosis with the Hamamatsu NanoZoomer S360MD Slide scanner. Approval in the US is conducted through a ‘closed-loop’ model, meaning that IMS software is required to be approved for use alongside specific scanners. Philips and Leica Biosystems hold a significant amount of market share in the US, so hopefully this approval will start to shake up competitive dynamics and stimulate some innovation!
That’s all for now, but as always feel free to comment if I’ve missed anything.
If you have any questions about these developments, or any of our reports (details below) and services, do feel free to drop me a message to set up a call.
And don’t forget to come and say hi if you see me in Baltimore at #USCAP!
Related Research
Digital Pathology Market Intelligence Service – World – 2024
Signify Research’s Market Intelligence Service provides a rolling 12-month coverage of the global Digital Pathology market. The service is composed of five deliverables and is designed to help you:
- Inform product investment and business strategy
- Evaluate the ever-changing competitive landscape to assess the impact of associations and select potential partners
- Acquire a holistic view of the nuances between different pathology research and clinical markets
- Understand adjacent markets such as enterprise imaging, laboratory information systems and the influence these will have on Digital Pathology
For any further questions or samples of the service contents, do drop me a note. 😊
About Imogen Fitt
Imogen joined Signify in 2018 as part of the Healthcare IT team. She holds a 1st class Biomedical Sciences degree from the University of Warwick where her studies included molecular biology and pharmacology. Since joining the team Imogen has studied the medical imaging software and hardware markets and is now expanding Signify Research’s Diagnostics and Lifesciences coverage.
About the Diagnostics and Lifesciences Team
The Diagnostics and Lifesciences team provides market intelligence and detailed insights on the multiple healthcare technology markets where the clinical world intersects with the preclinical. Our areas of coverage include digital pathology, laboratory information systems, clinical Real-World Data (cRWD) platforms, oncology information systems, tumour board software, oncology decision support software and radiotherapy IT. Each report provides a data-centric and global outlook of its markets with granular country-level insights. Our research process blends primary data collected from in-depth interviews with healthcare professionals and technology vendors, to provide a balanced and objective view of the market.
About Signify Research
Signify Research provides healthtech market intelligence powered by data that you can trust. We blend insights collected from in-depth interviews with technology vendors and healthcare professionals with sales data reported to us by leading vendors to provide a complete and balanced view of the market trends. Our coverage areas are Medical Imaging, Clinical Care, Digital Health, Diagnostic and Lifesciences and Healthcare IT.
Clients worldwide rely on direct access to our expert Analysts for their opinions on the latest market trends and developments. Our market analysis reports and subscriptions provide data-driven insights which business leaders use to guide strategic decisions. We also offer custom research services for clients who need information that can’t be obtained from our off-the-shelf research products or who require market intelligence tailored to their specific needs.
More Information
To find out more:
E: enquiries@signifyresearch.net
T: +44 (0) 1234 986111
www.signifyresearch.net